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Abstract
Introduction: Systemic lupus erythematosus is associated with a persistent circulation of modified autoantigen-
containing apoptotic debris that might be capable of breaking tolerance. We aimed to evaluate apoptotic
microvesicles obtained from lupus or control mice for the presence of apoptosis-associated chromatin modifications
and for their capacity to stimulate dendritic cells (DC) from lupus and control mice.
Method: Apoptotic microvesicles were in vitro generated from splenocytes, and ex vivo isolated from plasma of
both MRL/lpr lupus mice and normal BALB/c mice. Microvesicles were analyzed using flow cytometry. Bone
marrow-derived (BM)-DC cultured from MRL/lpr or BALB/c mice were incubated with microvesicles and CD40
expression and cytokine production were determined as measure of activation.
Results: Microvesicles derived from apoptotic splenocytes or plasma of MRL/lpr mice contained more modified
chromatin compared to microvesicles of BALB/c mice, and showed enhanced activation of DC, either from MRL/lpr
or BALB/c mice, and consecutively an enhanced DC-mediated activation of splenocytes. The content of apoptosis-
modified chromatin in microvesicles of apoptotic splenocytes correlated with their potency to induce interleukin-6
(IL-6) production by DC. Microvesicle-activated MRL/lpr DC showed a significant higher production of IL-6 and
tumor growth factor-β (TGF-β) compared to BALB/c DC, and were more potent in the activation of splenocytes.
Conclusion: Apoptotic microvesicles from MRL/lpr mice are more potent activators of DC, and DC from MRL/lpr
mice appear relatively more sensitive to activation by apoptotic microvesicles. Our findings indicate that aberrations
at the level of apoptotic microvesicles and possibly DC contribute to the autoimmune response against chromatin
in MRL/lpr mice.
Introduction
Systemic lupus erythematosus (SLE) is a systemic auto-
immune disease characterized by high levels of autoanti-
bodies against chromatin [1]. Disturbances in apoptosis
and the removal of apoptotic cells, leading to the persist-
ent presence of apoptotic debris in the circulation, have
been associated with the development of SLE in patients
and in mouse models [2,3]. Apoptosis involves the trans-
location of chromatin from the nucleus into MVs (MVs)
at the cell surface. In case of prolonged circulation of
apoptotic cells, the MVs can be released and expose their
contents to the immune system [4,5]. Chromatin is present
in the circulation of SLE patients and lupus mice [6-8].
Subsequent formation and deposition of chromatin-anti-
chromatin complexes, primarily in the skin and kidneys,
elicits devastating local inflammation [9,10].
By recognizing dying cells as a danger sign, the immune
system plays an important role in monitoring the health
status of an organism [11]. We have previously demon-
strated that apoptotic MVs can activate dendritic cells (DC)
by inducing an increased expression of co-stimulatory
molecules CD40 and CD86, and an increased production
of pro-inflammatory cytokines IL-6 and tumor necrosis
factor-α (TNF-α) [12,13]. The exposure of DC to different
types of apoptotic cells may guide the immune response
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towards tolerance or autoimmunity, and the corresponding
type of T cell polarization (Th1, Th2, Th17 or Treg) [14].
In the circulation, apoptotic MVs are part of a larger
population of MVs, which are defined as small particles
with a diameter of 100 to 1000 nm formed by blebbing
of the plasma membrane [15]. MVs are released by plate-
lets, red blood cells, endothelial cells, and T and B cells.
MVs play a role in coagulation, secretion of cytokines, and
intercellular communication. Changes in the concentration
or composition of circulating MVs have been associated
with rheumatoid arthritis, systemic sclerosis, polymyositis/
dermatomyositis, and SLE [16-19]. Studies on the contents
and role of circulating (apoptotic) MVs in lupus mice and
patients are scarce and largely limited to in vitro-generated
apoptotic MVs, which indeed contain lupus autoantigens,
such as chromatin, and are recognized by lupus-derived
autoantibodies [20-23].
Recognition of apoptotic chromatin by the immune
system could be facilitated by the generation of apoptosis-
associated post-translational modifications [24]. Previously,
we showed the relevance of apoptosis-associated chroma-
tin modifications. We identified histone H4-K8,12,16 ac,
H2B-K12ac, H3-K27me3 and conformational acetylated
chromatin epitopes as targets of antibodies present in the
serum of lupus mice and SLE patients [25-28]. The
identified chromatin modifications were enriched dur-
ing apoptosis and were present in circulating chromatin
in SLE patients. In addition, hyperacetylated nucleo-
somes, in contrast to normally acetylated nucleosomes,
were superior in maturation of DC, whereas a peptide
containing H4-K8ac,12 ac,16 ac led to acceleration of
disease onset and aggravation of disease symptoms in
pre-diseased lupus mice [25].
In the present study, we evaluated whether the impact
of apoptotic MVs on dendritic cells was different in
lupus mice compared to control mice. We compared both
apoptotic MVs, generated either in vitro or in vivo, and
DC from lupus and normal mice.
Materials and methods
Cell culture
Murine 32D clone 3 (32Dcl3) cells were cultured in
complete medium as described [13]. BALB/c, CBA and
MRL/lpr mice were purchased (Harlan, Blackthorn, UK),
and maintained under specific pathogen-free conditions
and handled according to the guidelines of the local eth-
ics committee of the Radboud University in Nijmegen.
The mice used in this study were 8 to 10 weeks old and
experienced no active lupus disease, which was deter-
mined by measuring anti-dsDNA antibodies in ELISA, as
previously described (25), and by measuring proteinuria
using Albustix (Siemens Healthcare Diagnostics, Munich,
Germany). Bone marrow-derived DC were obtained by
culturing bone marrow from the respective mice as
previously described [29,30]. Mixed lymphocyte reaction
(MLR) of MV-activated DC and CBA splenocytes was per-
formed as described earlier [13]. For proliferation assays,
splenocytes were labeled with carboxyfluorescein succini-
midyl ester (CFSE, Molecular Probes, Life Technologies,
Paisley, UK) according to the manufacturer’s protocol.
Induction of apoptosis and isolation of apoptotic
microvesicles
Apoptosis was induced by incubating cells for 16 hours
with 10 μM 4-nitroquinoline 1-oxide (4-NQO; Sigma-
Aldrich, Zwijndrecht, The Netherlands). Apoptosis was
measured using fluorescein isothiocyanate (FITC)-conju-
gated annexin V and propidium iodide (PI) according to
the manufacturers’ protocol (BioVision, Palo Alto, USA).
MVs were isolated from apoptotic 32Dcl3 cells and sple-
nocytes as described previously [13]. Shortly, cells were
removed by centrifugation for 10 minutes at 1,550 g at
4°C, and apoptotic MVs were isolated from the resulting
supernatant by centrifugation for 50 minutes at 15,700 g
(Sorvall RC-6 Centrifuge, SS34 rotor; Thermoscientific,
Waltham, USA) at 4°C. In addition, MVs were isolated
from frozen EDTA-plasmas of 8- to 10-week-old BALB/
c, CBA and MRL/lpr mice. For this, plasma samples
were centrifuged twice for 5 minutes at 500 g at 4°C to
remove residual cells, after which the supernatant was
centrifuged for 20 minutes at 20.800 g at 4°C (Eppendorf
5417R Centrifuge; Eppendorf, Hamburg, Germany). For
addition to DC, MVs were isolated according to the
method described above, subsequently the MV pellet was
resuspended in RPMI medium without FCS, and the
protein concentration was determined using the
bicinchoninic acid assay (Sigma-Aldrich). Hereafter,
FCS was added to the MV preparation to achieve a final
concentration of 10%. The effect of MVs on DC was de-
termined by adding equal amounts in protein equiva-
lents of MVs for 16 hours at day 8 of the DC culture.
Plasma-derived MVs isolated from 25 μl plasma of
MRL/lpr or BALB/c mice were reconstituted in 25 μl
medium, adjusted to acquire equal amounts in protein
equivalents, and 2 or 10 μl was added to DC in a 96-
well plate containing 200 μl medium per well. Lipopoly-
saccharide (LPS) (1 μg/ml; tlrl-3pelps, InvivoGen, San
Diego, USA) was used as a positive control.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and western blotting
Cell extracts were prepared by dissolving the pelleted MVs
in one volume of PBS and adding two volumes of 3 ×
Laemmli buffer (62.5 mM Tris-HCl pH 6.8, 25% glycerol,
2% SDS, 0.01% bromophenol Blue, 5% β-mercaptoethanol).
Samples were heated for 5 minutes at 95°C, resolved by
SDS-PAGE (18%) and transferred to nitrocellulose as previ-
ously described [25].
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Confocal and electron microscopy
For immune fluorescence staining, cytospun cells were
fixed with 2% paraformaldehyde, permeabilized with
0.3% Triton X-100 and incubated with the indicated
mouse chromatin monoclonal antibodies (mAbs) followed
by Alexa 488-conjugated goat anti-mouse Ig(H + L) (Life
Technologies, Naarden, The Netherlands). Samples were
visualized using a Leica SP5 confocal microscope (Leica,
Heidelberg, Germany). For transmission electron micros-
copy (TEM), MVs were fixed with 2.5% glutaraldehyde,
postfixed in cacodylate-buffered 1% OsO4 and incubated
with 50% alcohol/2% uranyl acetate. Subsequently,
samples were dehydrated and embedded in EPON 812.
Ultrathin sections were cut on an ultratome (Leica
Microsystems, Heidelberg, Germany) and samples were
examined by electron microscopy (Jeol 1200 EX2; Jeol,
Nieuw-Vennep, The Netherlands).
Flow cytometry and enzyme-linked immunosorbent
assay (ELISA)
MVs were washed using PBS with 0.1% BSA (PBA) and
incubated with the indicated lupus-mouse derived
mAbs or mouse IgG2A isotype (Sigma), followed by
Alexa 488-conjugated goat anti-mouse Ig(H + L) (Life
Technologies). MVs were also incubated with PE-
conjugated anti-CD3 (clone 17A2), anti-CD19 (clone
1D3) or rat IgG2A isotype (clone eBR2A) (all BD Bio-
sciences) or with FITC-conjugated annexin V according
to the manufacturers’ protocol (BioVision). If indicated,
FIX & PERM® (Life technologies) was used for fixation/
permeabilization of the MVs according to the manufac-
turer’s protocol. The size of the MV population was es-
timated by flow cytometry using calibrated nanobeads
(Spherotech, Lake Forest, IL, USA). The concentration
of MVs was determined by adding a known concentration
of calibrated beads (AccuCheck, Life Technologies) ac-
cording to the manufacturer’s protocol. Splenocytes
were washed with PBA and subsequently incubated with
PE-conjugated anti-CD3 in combination with FITC-
conjugated anti-CD4 (clone H129.19) or anti-CD8
(clone 53-6.7), or PE-conjugated anti-CD19 (all BD
Biosciences). DC were stained with PE-conjugated anti-
CD40 (clone FGK45.5; Miltenyi Biotec, Utrecht, The
Netherlands) and Alexa 647-conjugated anti-CD11c
(clone N418; Serotec, Oxford, UK). Samples were ana-
lyzed using a FACSCalibur flow cytometer (BD Biosci-
ences, San Jose, CA, USA). Levels of TNF-α, IL-6, and
transforming growth factor (TGF)-β in supernatants of
DC cultures, or IFN-γ in supernatants from MLR
cultures, were determined in ELISA according to the
manufacturer’s protocol (eBioscience, San Diego, CA,
USA). Relative production was calculated compared to
the respective unstimulated DC, and expressed as fold-
induction.
Statistical analysis
Values are expressed as mean ± standard error of the mean
(SEM), and significance was determined by Student’s t-test
or Mann-Whitney U-test using GraphPad Prism (Graph-
Pad Software, San Diego, CA, USA). P-values less than
0.05 were considered as statistically significant.
Results
The 32Dcl3-derived microvesicles contain apoptosis-
associated chromatin modifications
Apoptotic MVs from 4-NQO-treated 32Dcl3 granulocyte
cells were stained with lupus mouse-derived mAbs #34
(anti-H3.1) [31], KM-2 (anti-H2A/H4-K8,12,16 ac) [25],
BT164 (anti-H3-K27me3) [26], and LG11-2 (anti-H2B-
K12ac) [27]. Note that we have previously associated the
chromatin modifications recognized by KM-2, LG11-2
and BT164 with apoptosis and SLE [25-27]. The gated
population of MVs (Figure 1A) stained positive for the
tested mAbs (Figure 1B) with some degree of variability
(Figure 1C). Western blot analysis (Figure 1D) confirmed
the presence of apoptosis-modified histones in 32Dcl3-
derived MVs. Permeabilization and fixation did not sig-
nificantly alter the MV population based on the FSC/
SSC plot and the staining by any of the mAbs (Figure 1E,
LG11-2 is shown as a representative example). In con-
focal microscopy, the (modified) histones appeared pri-
marily located on the outer rim of MVs that were still
attached to the apoptotic cell (Figure 1F). Analysis of
32Dcl3-derived MVs by electron microscopy showed a
large variety of MVs, of which a representative example
is shown in Figure 1G. The median size of the isolated
MVs, as observed in multiple electron microscopy pic-
tures, was 422 nm, with only 3.4% of the MVs below
0.1 μm and 0.4% above 1 μm (Figure 1H). In summary,
we detected apoptosis-associated chromatin modifica-
tions in 32Dcl3-derived apoptotic MVs that were located
predominantly at the outer rim of MVs.
MRL/lpr DC are relatively more sensitive to activation by
32Dcl3-derived than BALB/c DC
The response of cultured DC from lupus mice and nor-
mal mice to MVs from 4-NQO-treated 32Dcl3 cells re-
vealed induction of CD40 that was significantly higher in
MRL/lpr DC using 50 μg/ml MVs, while it was compar-
able with normal mice using 100 μg/ml MVs or LPS
(Figure 2A and B). MRL/lpr DC that were unstimulated
or stimulated with LPS, produced significantly lower IL-
6 levels compared to BALB/c DC (Figure 2C). However,
the induction of IL-6 by MVs was 2- to 3-fold higher in
MRL/lpr DC compared with BALB/c DC (Figure 2D).
TNF-α was also induced by addition of MVs, but with
no significant differences between MRL/lpr and BALB/c
DC (Figure 2E and F). MRL/lpr DC seem to produce
lower basal levels of TGF-β compared with BALB/c DC
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(P = 0.10), while MVs tended to induce a higher TGF-β
production in MRL/lpr DC (P = 0.14) (Figure 2G and H).
In conclusion, with respect to CD40 upregulation and
IL-6 production, DC from MRL/lpr mice appeared to be
relatively more sensitive to stimulation by 32Dcl3-
derived MVs than BALB/c DC.
Splenocyte-derived apoptotic microvesicles from MRL/lpr
mice expose more chromatin than those from BALB/c mice
MRL/lpr (8- to 10-week-old) splenocyte-derived MVs
demonstrated a higher mean fluorescence intensity (MFI)
after staining with mAb #34 (against unmodified chroma-
tin), and with KM-2, BT164 and LG11-2 (all against
apoptosis-modified chromatin), when compared to MVs
derived from BALB/c or C57BL/6 splenocytes (Figure 3A).
We did not observe obvious differences in the MV popu-
lation of MRL/lpr and BALB/c mice in forward scatter
(FSC)/side scatter (SSC) plots (Figure 3B). MV-generating
apoptotic splenocytes were in a comparable phase of
apoptosis (Figure 3C) and the percentage of apoptotic
MVs originating from splenocytic T or B cells was com-
parable for MRL/lpr and BALB/c (Figure 3D). In sum-
mary, apoptotic MVs generated in vitro from splenocytes
of MRL/lpr mice expose more (modified) chromatin com-
pared to BALB/c splenocytes.
Splenocyte-derived apoptotic microvesicles from MRL/lpr
mice are more potent activators of DC than microvesicles
from BALB/c mice
In MRL/lpr DC, MRL/lpr splenocyte-derived MVs induced
a significantly higher expression of CD40 than BALB/c
splenocyte-derived MVs (Figure 4A). Splenocyte-derived
MVs of both BALB/c and MRL/lpr mice induced a
significantly higher expression of CD40 in MRL/lpr
DC, compared to BALB/c DC (Figure 4B). MRL/lpr
splenocyte-derived MVs induced production of IL-6 and
TNF-α in both MRL/lpr and BALB/c DC, while BALB/c
MVs had no significant effect (Figure 4C and E). The MV-
induced IL-6 production tended to be more pronounced
in MRL/lpr DC (P = 0.06) (Figure 4D), but this was not
the case for TNF-α (P = 0.84) (Figure 4F). Both MRL/lpr
and BALB/c MVs significantly induced TGF-β production
in MRL/lpr DC, but not in BALB/c DC (Figure 4G and
H). There was correlation between the MV-induced pro-
duction of IL-6 by DC and the MFI of the respective MV-
samples for mAbs BT164 (r2 = 0.53, P = 0.02) and LG11-2
(r2 = 0.49, P = 0.03). Taken together, MVs derived from
MRL/lpr splenocytes, and not those from BALB/c spleno-
cytes, were able to activate DC. The potency to induce the
pro-inflammatory cytokine IL-6 appeared to be correlated
with the amount of exposed apoptosis-modified chroma-
tin in the MVs. As described above for 32Dcl3-derived
MVs, MRL/lpr DC also appeared relatively more sensitive
to activation by splenocyte-derived MVs.
Plasma-derived microvesicles from MRL/lpr mice expose
more chromatin than microvesicles in plasma from
BALB/c mice
The concentration of MVs from plasma of MRL/lpr and
BALB/c mice analyzed by flow cytometry revealed a linear
correlation with the protein concentration using 32Dcl3-
derived MVs as a standard (Figure 5A). A protein equiva-
lent of 100 μg/ml of 32Dcl3-derived MVs corresponded to
approximately 105 MVs/μl, which was comparable to the
mean concentration of MVs in plasma of BALB/c mice,
while MRL/lpr mice tended to have higher concentrations
(p = 0.052) (Figure 5B). Plasma-derived MVs did not show
large differences in the FSC/SSC plot between both mice
strains (Figure 5C). Although the total Annexin V++
population showed no proportional difference, MRL/lpr
MVs contained a significantly higher percentage of Annexin
V++/CD3+ (T cell-derived) and Annexin V++/CD19+ (B
cell-derived) MVs compared to BALB/c MPs (Figure 5D).
Annexin V++/CD3+ and Annexin V++/CD19+ MVs formed
together approximately 90% of the total population of
Annexin V++ MVs. Importantly, MRL/lpr plasma also
contained a higher percentage of MVs positive for our
panel of anti-chromatin mAbs (Figure 5E). The mean
(See figure on previous page.)
Figure 1 Apoptotic microvesicles derived from 32Dcl3 cells contain modified chromatin. (A) Forward scatter/side scatter (FSC/SSC) plot of
microvesicles isolated from apoptotic 32Dcl3 cells, indicating the size of the microvesicle population (gray) according to calibrated nanobeads
with the indicated size in μm (black). (B) 32Dcl3-derived apoptotic microvesicles were stained in flow cytometry for lupus mouse-derived mAbs
#34, KM-2, BT164 and LG11-2. Histograms for a representative experiment are shown and the isotype control is indicated in each graph (fine line).
(C) Mean fluorescence intensity (MFI) of for the indicated mAbs in multiple experiments (n = 10) showing the signal-range (25 to 75%) between
different microvesicle preparations. (D) Extracts of 32Dcl3-derived apoptotic microvesicles were probed in western blot with the indicated lupus
mouse-derived mAbs to confirm the presence of apoptosis-modified histones. The expected position of the respective histones is indicated on
the left side. (E) 32Dcl3-derived apoptotic microvesicles were either directly stained (no fix/perm), or fixed and permeabilized before staining
(fix/perm), and show no differences for the signal of LG11-2. FSC/SSC plots of the microvesicle population for both conditions are indicated on
the left. On the right a representative histogram is shown for the isotype control (not filled) and mAb LG11-2 (filled) for microvesicles without
(black line) or with fixation/permeabilization (gray line). (F) Confocal microscopy of 32Dcl3 cells stained with mAb KM-2. Apoptotic microvesicles
still attached to early apoptotic 32Dcl3 cells are indicated (arrowheads). (G) Ultra-structural analysis of isolated 32Dcl3-derived apoptotic
microvesicles by electron microscopy. Bar, 3 μm. (H) Median size of isolated microvesicles as determined by measuring the size in multiple
electron microscopy pictures.
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fluorescent intensity/MV for mAb #34 and KM-2 was
significantly higher for MRL/lpr MVs, while BT164 also
tended to be higher (Figure 5F). For LG11-2, we observed
a high mean fluorescent intensity, but a lower percentage
of LG11-2-positive MVs in BALB/c mice, which was due
to a small (unidentified) subpopulation of MVs. In sum-
mary, plasma from MRL/lpr mice contain an increased
percentage of CD3+/CD19+ MVs with an increased
amount of (modified) chromatin compared with MVs in
plasma of BALB/c mice.
(See figure on previous page.)
Figure 2 MRL/lpr dendritic cells (DC) are more prone to activation by 32Dcl3-derived apoptotic microvesicles, compared to BALB/c DC. CD40
expression (A), and IL-6 (C), TNF-α (E) and transforming growth factor (TGF)-β (G) levels produced by BALB/c and MRL/lpr DC were measured
after stimulation with the indicated concentration of 32Dcl3-derived apoptotic microvesicles. The relative CD40 expression (B), and IL-6 (D), TNF-α
(F) and TGF-β (H) levels of microvesicle- or lipopolysaccharide (LPS)-stimulated MRL/lpr DC were compared to BALB/c DC. *P <0.05 compared to
unstimulated DC, $P <0.05 compared to DC from BALB/c. MFI, mean fluorescence intensity.
Figure 3 Splenocyte-derived apoptotic microvesicles from MRL/lpr mice contain more (modified) chromatin compared to BALB/c splenocyte-derived
microvesicles. (A) Microvesicles from apoptotic splenocytes of 8- to 10-week-old MRL/lpr mice (n = 12) were stained for lupus-mouse derived
mAbs #34, KM-2, BT164 and LG11-2, and compared to splenocytes from BALB/c (n = 11) and C57Bl/6 mice (n = 7). *P <0.05. (B) Representative
example of a forward scatter/side scatter (FSC/SSC) plot for BALB/c and MRL/lpr splenocyte-derived apoptotic microvesicles demonstrating
comparable microvesicle-populations. (C) 4-NQO-induced apoptosis for BALB/c and MRL/lpr splenocytes after 16 hours was determined by
flow cytometry using annexin V-fluorescein isothiocyanate (FITC) and propium iodide (PI). (D) The percentage of CD3- and CD19-positive
apoptotic microvesicles for splenocytes of MRL/lpr and BALB/c mice 16 hours after induction of apoptosis was measured by flow cytometry.
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Figure 4 Splenocyte-derived apoptotic microvesicles from MRL/lpr mice, and not those from BALB/c mice, are able to activate MRL/lpr dendritic
cells (DC), that are also more prone to activation compared to BALB/c DC. CD40 expression (A), and IL-6 (C), TNF-α (E) and transforming growth
factor (TGF)-β (G) levels produced by BALB/c and MRL/lpr DC were measured after stimulation with the indicated concentration of splenocyte-derived
apoptotic microvesicles. The relative CD40 expression (B), and IL-6 (D), TNF-α (F) and TGF-β (H) levels of microvesicle- or LPS-stimulated MRL/lpr
DC were compared to BALB/c DC.*P <0.05 compared to unstimulated DC, $P <0.05 compared to DC from BALB/c. MFI, mean fluorescence intensity.
Figure 5 Plasma-derived microvesicles (MVs) from MRL/lpr mice expose a higher amount of chromatin and contain a higher percentage of
annexin V++/CD3+ and annexin V++/CD19+ MVs. (A) The concentration of apoptotic MVs derived from 32Dcl3 cells determined in flow cytometry
using counting beads (y-axis) was compared to the protein concentration of the same MV samples measured by the BCA assay (x-axis). (B) The
concentration of MVs isolated from apoptotic 32Dcl3 cells, brought to a concentration of 100 μg protein/ml, and from plasma of 8- to 10-week-old
BALB/c and MRL/lpr mice were determined by flow cytometry. (C) Representative forward scatter/side scatter (FSC/SSC) plots obtained from
plasma-derived MVs of a BALB/c and MRL/lpr mouse to demonstrate comparable MV populations. (D) The percentage of MVs positive for
Annexin V, anti-CD3-PE or anti-CD19-PE, was measured by flow cytometry for MRL/lpr mice in comparison to BALB/c mice (both n = 8).
(E, F) Flow cytometry of plasma-derived MVs from BALB/c and MRL/lpr mice after staining with the indicated mAbs. The percentage positive
MVs (E) and the mean fluorescence intensity (MFI) (F) of MRL/lpr MVs was compared to BALB/c microvesicles. *P <0.05; **P <0.01.
Dieker et al. Arthritis Research & Therapy  (2015) 17:103 Page 9 of 14
Plasma-derived microvesicles of MRL/lpr mice are more
potent activators of DC and splenocytes than
microvesicles from BALB/c mice
Only MVs from MRL/lpr mice were able to induce a sig-
nificant CD40 expression in both BALB/c and MRL/lpr
DC (Figure 6A). MV-induced CD40 expression was not
significantly higher in MRL/lpr DC, however, a trend
could be seen for the highest concentration of MRL/lpr
MVs (Figure 6B). Plasma-derived MVs from MRL/lpr
mice also induced the production of IL-6 and TNF-α,
while MVs from BALB/c mice induced only a small in-
crease (Figure 6C and E). Calculation of the ratio of MV-
induced cytokine production compared to unstimulated
DC confirmed that the MV-induced relative increase in
IL-6 production was considerably higher for MRL/lpr DC
compared to BALB/c DC (Figure 6D). The MV-induced
relative increase in TNF-α did not differ between MRL/lpr
and BALB/c DC (Figure 6F). Plasma of 13- and 18-weeks-
old BALB/c and MRL/lpr mice essentially gave similar re-
sults (data not shown). In addition, MVs from both MRL/
lpr and BALB/c mice induced TGF-β in MRL/lpr DC
(Figure 6G and H). Finally, we compared the splenocyte-
activating capacity of DC incubated with 32Dcl3- or
plasma-derived MVs (Figure 7). MRL/lpr DC incubated
with 32Dcl3- or plasma-derived MVs from MRL/lpr mice
induced a 10-20-fold increase in IFN-γ production by
MHC-mismatched CBA splenocytes (Figure 7A). BALB/c
DC and/or BALB/c MVs reduced or induced only a small
increase in the production of IFN-γ. Similar trends could
be observed for the proliferation of splenocytes after incu-
bation with MV-stimulated DC, although these differences
were rather small for DC stimulated with plasma-derived
MVs (Figure 7B). In summary, plasma-derived MVs from
MRL/lpr mice are more potent stimulators of DC activa-
tion, in particular it seems of MRL/lpr DC, compared to
MVs derived from BALB/c mice.
Discussion
We observed that both in vitro-generated and ex vivo-
isolated MVs from MRL/lpr mice contained an increased
amount of accessible (modified) chromatin compared to
MVs from BALB/c mice. Chromatin in MVs of MRL/lpr
mice might posses a more open structure due to an in-
creased acetylation of histones H2A/H4 and H2B, which
we observed here. For the in vitro-generated MVs, we
could exclude differences in rate/stage of apoptosis, in
composition of splenocytes (data not shown), and in a
subset of splenocytes going into apoptosis, as sources for
the increased amount of chromatin. Apoptotic MVs
from both MRL/lpr and BALB/c mice still contained in-
tact nucleosomes and dsDNA (data not shown), which
excludes a large-scale breakdown of nucleosomes as a
source of increased accessibility. Dysfunctional apoptotic
processing could lead to other structural differences of
chromatin in MVs of lupus mice; for example, a reduced
fragmentation of apoptotic chromatin has been demon-
strated in kidneys of NZBW/F1 lupus mice [32]. How-
ever, future research has to determine the exact cause
for the increased amount or accessibility of (modified)
chromatin in apoptotic MVs from MRL/lpr mice.
In plasma from both 8- to 10-week-old BALB/c and
MRL/lpr mice there is a similar number of MVs that are
highly positive for Annexin-V. Another study also ob-
served that BALB/c and lupus mice contained comparable
amounts of MVs [23]. In addition, we have previously
shown that apoptotic nucleosomes can be detected both
in the circulation of BALB/c and MRL/lpr mice at a young
age [8]. MRL/mpj mice have a similar genetic background
to MRL/lpr, and are often used as control mice. However,
MRL/mpj mice have defective removal of apoptotic cells
that is similar to MRL/lpr mice [33,34]. In addition, as
with MRL/lpr mice, MRL/mpj mice have persistent high
levels of apoptotic nucleosomes in their circulation at a
later age [8]. Therefore, we chose to use BALB/c mice as
control mice for this study. As the concentration of MVs
in MRL/lpr mice and BALB/c mice is similar, the immu-
nostimulatory capacity of circulating (apoptotic) MVs in
murine SLE could be explained by differences in compos-
ition. Indeed, we show that the proportion of circulating
apoptotic MVs that is derived from B and T cells, is sig-
nificantly higher for MRL/lpr mice compared to BALB/c
mice. This may be explained by an increased number of
lymphocytes that escape selection in the thymus and enter
the circulation of MRL/lpr mice [35,36]. Moreover, the
vast majority of circulating apoptotic MVs appeared to be
derived from T or B cells, whereas we did not detect a sig-
nificant amount of endothelial-derived MVs (not shown).
To our knowledge, increases in B or T cell-derived apop-
totic MVs have not been described in lupus mice or SLE
patients. In addition, CD3- or CD19-positive MVs are
elevated in patients with other autoimmune diseases
[16,37] and patients with chronic lymphoproliferative
diseases [38].
We have previously shown that apoptotic MVs from
32Dcl3 cells are capable of maturing DC from normal
mice, leading to a mixed Th1/Th17 response [12,13].
We now show that in vitro-generated MVs and ex vivo-
isolated MVs derived from MRL/lpr mice were more po-
tent activators of DC than MVs and MVs from BALB/c
mice. In fact, MVs derived from BALB/c mice, showed
virtually no activation of DC. In addition, DC-mediated
activation of splenocytes was also increased after incuba-
tion with MRL/lpr MVs. Importantly, MVs were isolated
from 8- to 10-week-old pre-diseased MRL/lpr mice that
did not possess detectable amounts of anti-DNA autoanti-
bodies in their circulation (data not shown), to exclude a
contribution of immune complexes in the activation of
DC. In addition, we found no MV-bound IgG in 8- to
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Figure 6 (See legend on next page.)
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10-week-old MRL/lpr mice, using a labeled anti-mouse
IgG antibody (data not shown), which has been de-
scribed for MRL/lpr mice >14 weeks old [23]. The
observed correlation between the amount of exposed
chromatin in splenocyte-derived MVs and their potency
to induce IL-6 suggests that the increased exposure of
apoptosis-modified chromatin on MRL/lpr MVs might
be related to their increased immunogenicity. Indeed,
histones are capable of activating the innate immune
system [39,40]. Moreover, we have previously shown that
acetylation of histones and chromatin increases their im-
munogenicity in vitro and in vivo [25]. Interestingly, Fehr
et al. have recently demonstrated a different modulating
effect of apoptotic MVs, which were ex vivo-generated
from human lymphocytes, on DC from healthy individuals
and SLE patients [41].
Our finding that MRL/lpr DC produced lower basal
and LPS-induced levels of IL-6 is in accordance with a
previous study showing that DC from lupus mice, in-
cluding MRL/lpr and MRL/mpj, produce lower levels of
IL-6 in response to several toll-like receptor (TLR)-li-
gands [42]. This was attributed to a diminished ability to
sustain IκBα phosphorylation, resulting in lower levels of
IL-6 mRNA. Lower production of IL-6 in response to
CpG has also been found in peripheral blood mono-
nuclear cells from SLE patients [43]. In contrast to the
lower basal levels, the fold-induction of IL-6 by in vitro-
generated and ex vivo-isolated apoptotic MVs was rela-
tively higher in MRL/lpr DC compared to BALB/c DC.
Notably, IL-6 plays a dual role because it is involved
both in immunity and tolerance. IL-6 is essential for the
induction of a Th17 response and suppression of Treg
[44], but also regulates the maturation of DC [45,46]. IL-6
knockout mice show increased numbers of matured DC
[45]. Therefore, lower basal IL-6 production by DC might
affect their differentiation/maturation and render them
more susceptible to certain stimuli, whereas the subse-
quently enhanced IL-6 production might promote a Th17
response. Our findings indicate that TGF-β, a cytokine
that is also able to inhibit DC maturation and which coop-
erates with IL-6 to induce a Th17 response, behaved quite
similarly to IL-6 in MRL/lpr DC. In contrast, the MV-
induced production of TNF-α was not enhanced in MRL/
lpr DC. This may be explained by the fact that the path-
ways used to induce IL-6 and TNF can differ [47].
Conclusions
We showed that in the MRL/lpr lupus mouse model,
apoptotic MVs are more potent activators of DC,
which was associated with an increased content of
apoptosis-modified chromatin. Our data suggest that
the composition of the chromatin in MVs dictates
Figure 7 Dendritic cell (DC)-mediated splenocyte activation is increased in MRL/lpr DC stimulated with plasma-derived microvesicles from
MRL/lpr mice. (A) Relative IFN-γ production of CBA splenocytes was measured after incubation with microvesicle (MV)-stimulated DC and
compared to splenocytes incubated with unstimulated DC. (B) Relative proliferation of carboxyfluorescein succinimidyl ester (CFSE)-labeled CBA
splenocytes was determined in mixed lymphocyte reaction after incubation with MV-stimulated DC and compared to splenocytes incubated with
unstimulated DC. *P <0.05.
(See figure on previous page.)
Figure 6 Microvesicles (MVs) isolated from plasma of MRL/lpr mice are more potent in activating dendritic cells (DC) compared to BALB/c
microvesicles. CD40 expression (A) and IL-6 (C) TNF-α (E) and transforming growth factor (TGF)-β (G) levels produced by BALB/c and MRL/lpr DC
were measured after stimulation with the indicated MVs. The relative CD40 expression (B) and IL-6 (D) TNF-α (F) and TGF-β (H) levels of MV- or
lipopolysaccharide (LPS)-stimulated MRL/lpr DC were compared to BALB/c DC. *P <0.05 compared to unstimulated DC or BALB/c plasma-derived
microvesicles, $P <0.05 compared to BALB/c DC.
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their immunogenicity. Breaking the tolerance in MRL/
lpr mice might also be facilitated by a relative en-
hanced sensitivity of their DC for these immunogenic
apoptotic MVs. Future studies into the exact properties of
the immunogenic apoptotic MVs and their receptors on
DC, in particular also in SLE patients, should lead to a
better insight into the processes that result in breaking of
tolerance in SLE.
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